Phenotypic differences between fast and slow methionine sulfoximine-inbred mice: Seizures, anxiety, and glutamine synthetase

Epilepsy Research

Volumn 98, Issue 1, 2012, Pages 25-34

  Boissonnet, Arnaud ^a,b   Hévor, Tobias ^a   Cloix, Jean François ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b Glycodiag   (France)

Author keywords

Behaviour; Convulsants; Epilepsy; Glutamate glutamine cycle; Glutamatergic pathways; Open field

Indexed keywords

ANTICONVULSIVE AGENT; CONVULSANT AGENT; DIZOCILPINE; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLUTAMINE; KAINIC ACID; METHIONINE SULFOXIMINE; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONSANGUINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME KINETICS; EPILEPTOGENESIS; FEMALE; GABAERGIC SYSTEM; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEIZURE; STRAIN DIFFERENCE;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; FEMALE; GLUTAMATE-AMMONIA LIGASE; MALE; METHIONINE SULFOXIMINE; MICE; MICE, INBRED STRAINS; SEIZURES;

EID: 83555178460     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.08.012     Document Type: Article

References (49)

1. Andrade D.M., Minassian B.A. Genetics of epilepsies. Expert Rev. Neurother. 2007, 7:727-734.
2. Armijo J.A., Shushtarian M., Valdizan E.M., Cuadrado A., de las Cuevas I., Adin J. Ion channels and epilepsy. Curr. Pharm. Des. 2005, 11:1975-2003.
3. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 2001, 125:141-149.
4. Bidmon H.J., Gorg B., Palomero-Gallagher N., Schleicher A., Haussinger D., Speckmann E.J., Zilles K. Glutamine synthetase becomes nitrated and its activity is reduced during repetitive seizure activity in the pentylentetrazole model of epilepsy. Epilepsia 2008, 49:1733-1748.
5. Blin M., Crusio W.E., Hevor T., Cloix J.-F. Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice. Brain Res. Bull. 2002, 57:11-15.
6. Chapouthier G., Launay J.M., Venault P., Breton C., Roubertoux P.L., Crusio W.E. Genetic selection of mouse lines differing in sensitivity to a benzodiazepine receptor inverse agonist. Brain Res. 1998, 787:85-90.
7. Cloix J.F., Hevor T. Epilepsy, regulation of brain energy metabolism and neurotransmission. Curr. Med. Chem. 2009, 16:841-853.
8. Cloix J.F., Tahi Z., Boissonnet A., Hevor T. Brain glycogen and neurotransmitter levels in fast and slow methionine sulfoximine-selected mice. Exp. Neurol. 2010, 225:38-47.
9. Cloix J.F., Tahi Z., Martin B., Hevor T. Selection of two lines of mice based on latency to onset of methionine sulfoximine seizures. Epilepsia 2010, 51:118-128.
10. Crusio W.E. Genetic dissection of mouse exploratory behaviour. Behav. Brain Res. 2001, 125:127-132.
11. Dalsgaard M.K., Madsen F.F., Secher N.H., Laursen H., Quistorff B. High glycogen levels in the hippocampus of patients with epilepsy. J. Cereb. Blood Flow Metab. 2007, 27:1137-1141.
12. Duvoisin R.M., Pfankuch T., Wilson J.M., Grabell J., Chhajlani V., Brown D.G., Johnson E., Raber J. Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav. Brain Res. 2010, 212:168-173.
13. Eid T., Ghosh A., Wang Y., Beckstrom H., Zaveri H.P., Lee T.S., Lai J.C., Malthankar-Phatak G.H., de Lanerolle N.C. Recurrent seizures and brain pathology after inhibition of glutamine synthetase in the hippocampus in rats. Brain 2008, 131:2061-2070.
14. Einat H., Manji H.K., Gould T.D., Du J., Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect. 2003, 16:453-463.
15. Engelsen B., Fonnum F. The effect of methionine sulfoximine, an inhibitor of glutamine synthetase, on the levels of amino acids in the intact and decorticated rat neostriatum. Brain Res. 1985, 338:165-168.
16. Folbergrova J., Passonneau J.V., Lowry O.H., Schulz D.W. Glycogen, ammonia and related metabolites in the brain during seizures evoked by methionine sulphoximine. J. Neurochem. 1969, 16:191-203.
17. Fonnum F., Paulsen R.E. Comparison of transmitter amino acid levels in rat globus pallidus and neostriatum during hypoglycemia or after treatment with methionine sulfoximine or gamma-vinyl gamma-aminobutyric acid. J. Neurochem. 1990, 54:1253-1257.
18. Griffith O.W., Meister A. Differential inhibition of glutamine and gamma-glutamylcysteine synthetases by alpha-alkyl analogs of methionine sulfoximine that induce convulsions. J. Biol. Chem. 1978, 253:2333-2338.
19. Guillot P.V., Sluyter F., Crusio W.E., Chapouthier G. Mice selected for differences in sensitivity to a benzodiazepine receptor inverse agonist vary in intermale aggression. Neurogenetics 1999, 2:171-175.
20. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
21. Hevor T.K. Some aspects of carbohydrate metabolism in the brain. Biochimie 1994, 76:111-120.
22. Hixson J.D., Kirsch H.E. The effects of epilepsy and its treatments on affect and emotion. Neurocase 2009, 15:206-216.
23. Kanner A.M. The use of psychotropic drugs in epilepsy: what every neurologist should know. Semin. Neurol. 2008, 28:379-388.
24. Kanner A.M. Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders, and epilepsy. Epilepsy Behav. 2009, 15:83-87.
25. Krystal J.H., Mathew S.J., D'Souza D.C., Garakani A., Gunduz-Bruce H., Charney D.S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24:669-693.
26. LaFrance W.C., Kanner A.M., Hermann B. Psychiatric comorbidities in epilepsy. Int. Rev. Neurobiol. 2008, 83:347-383.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
28. Mares P., Mikulecka A., Ticha K., Lojkova-Janeckova D., Kubova H. Metabotropic glutamate receptors as a target for anticonvulsant and anxiolytic action in immature rats. Epilepsia 2010, 51(Suppl. 3):24-26.
29. Martinez-Hernandez A., Bell K.P., Norenberg M.D. Glutamine synthetase: glial localization in brain. Science 1977, 195:1356-1358.
30. McNamara J.O., Huang Y.Z., Leonard A.S. Molecular signaling mechanisms underlying epileptogenesis. Sci. STKE 2006, 2006:re12.
31. Meldrum B. Status epilepticus: the past and the future. Epilepsia 2007, 48(Suppl. 8):33-34.
32. Mohler H. GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J. Recept. Signal Transduct. Res. 2006, 26:731-740.
33. Moult P.R. Neuronal glutamate and GABAA receptor function in health and disease. Biochem. Soc. Trans. 2009, 37:1317-1322.
34. Mula M., Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord. 2009, 11:1-9.
35. Phelps C.H. An ultrastructural study of methionine sulphoximine-induced glycogen accumulation in astrocytes of the mouse cerebral cortex. J. Neurocytol. 1975, 4:479-490.
36. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
37. Reid C.A., Berkovic S.F., Petrou S. Mechanisms of human inherited epilepsies. Prog. Neurobiol. 2009, 87:41-57.
38. Rossler A.S., Schroder H., Dodd R.H., Chapouthier G., Grecksch G. Benzodiazepine receptor inverse agonist-induced kindling of rats alters learning and glutamate binding. Pharmacol. Biochem. Behav. 2000, 67:169-175.
39. Scharfman H.E. The neurobiology of epilepsy. Curr. Neurol. Neurosci. Rep. 2007, 7:348-354.
40. Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav. 2009, 15:56-65.
41. Sierra-Paredes G., Sierra-Marcuno G. Extrasynaptic GABA and glutamate receptors in epilepsy. CNS Neurol. Disord. Drug Targets 2007, 6:288-300.
42. Somers D.L., Beckstead R.M. Chronic methionine sulfoximine administration reduces synaptosomal aspartate and glutamate in rat striatum. Neurosci. Lett. 1990, 115:335-340.
43. Stafstrom C.E. Epilepsy: a review of selected clinical syndromes and advances in basic science. J. Cereb. Blood Flow Metab. 2006, 26:983-1004.
44. Velisek L., Veresova S., Pobisova H., Mares P. Excitatory amino acid antagonists and pentylenetetrazol-induced seizures during ontogenesis. II. The effects of MK-801. Psychopharmacology (Berl) 1991, 104:510-514.
45. Venault P., Beracochea D., Valleau M., Joubert C., Chapouthier G. Mouse lines selected for difference in sensitivity to beta-CCM also differ in memory processes. Behav. Brain Res. 2006, 173:282-287.
46. Venault P., Chapouthier G. Plasticity and anxiety. Neural Plast. 2007, 2007:75617.
47. Vincent P., Mulle C. Kainate receptors in epilepsy and excitotoxicity. Neuroscience 2009, 158:309-323.
48. Wieronska J.M., Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem. Int. 2009, 55:85-97.
49. Wolfe L.S., Elliot K.A.C. Chemical studies in regulation to convulsive conditions. Neurochemistry 1962, 694-697. Springfield, USA. 2nd ed. K.A.C. Elliot, I.H. Page, J.H. Quastel (Eds.).